Skip to main content
. 2021 Sep 20;47:102132. doi: 10.1016/j.redox.2021.102132

Fig. 9.

Fig. 9

Transient PARP inhibition improved IR (localized 5 Gy twice)-induced cardiac dysfunction after TAC.(A) Echocardiographic parameters after IR and TAC. LV: left ventricular, LVAW; s: LV end-systolic anterior wall thickness, LVAW; d: LV end-diastolic anterior wall thickness, LVPW; s: LV end-systolic posterior wall thickness, LVPW; d: LV end-diastolic posterior wall thickness. (B) LV mass (left), LVAW; d (middle), and LVPW; d (right) before and after TAC from the non-IR after TAC, IR after TAC, and IR + olaparib treatment after TAC groups. The data are mean ± SD, n = 6–21, **P < 0.01 and *P < 0.05. (C) Representative M-mode echocardiograph from the non-IR after TAC, IR after TAC, and IR + olaparib treatment after TAC groups. (D) Representative B-mode images of a mouse heart in the parasternal long axis with infarct (IR after TAC group) or without infarct (non-IR after TAC group), showing the thin ventricular wall and akinesis in the apex area. (E) Representative Masson trichrome stained heart from the IR + vehicle treatment group after TAC.